Epigenetic Alteration a Promising New Drug Target for Heroin Use Disorder
Reports new study in Biological Psychiatry
Reports new study in Biological Psychiatry
The past few years have seen an explosion of heroin abuse and deaths from opiate overdose. But little is known about the molecular underpinnings of heroin addiction. A new study in Biological Psychiatry found that heroin use is associated with excessive histone acetylation, an epigenetic process that regulates gene expression. More years of drug use correlated with higher levels of hyperacetylation. The study, led by Dr. Yasmin Hurd of the Icahn School of Medicine at Mount Sinai, New York, provides the first direct evidence of opiate-related epigenetic alterations in the human brain.
To narrow in on these alterations, first author Dr. Gabor Egervari and colleagues studied postmortem human tissue — a challenging but critical endeavor for understanding the molecular organization of the human brain — from 48 heroin users and 37 controls. They focused on the striatum, a brain region implicated in drug addiction because of its central role in habit formation and goal-directed behavior.
The acetylation changes were observed at genes that mediate glutamatergic function, specifically the glutamate receptor gene GRIA1, which has previously been implicated in drug use. The epigenetic impairments reflect changes that increase accessibility of chromatin, a process that enhances gene transcription, suggesting the impairments play an important role in addiction behavior.
“At this time, when prescription opioid use and opioid overdoses are both major threats to our public health, it is important to identify new treatment targets, such as epigenetic processes, that help to change the way that we do business in treating opioid use disorders,” said professor John Krystal, Editor of Biological Psychiatry.
“Epigenetic marks are physical alterations to the DNA that do not change the sequence of a gene, and thus have the potential to be reversed,” said Hurd. So the researchers used a rat model of heroin addiction to test this idea. Importantly, rats allowed to self-administer heroin displayed the same hyperacetylation alterations that were found in the human brains.
Dr. Egervari and colleagues treated the rats with JQ1, a compound originally developed against cancer pathology, which inhibits acetylation. The drug reduced self-administered heroin taking in the rats. Importantly, JQ1 also reduced drug-seeking behavior after abstinence from heroin, suggesting it might be beneficial for long-term heroin users.
“Our findings suggest that JQ1 and similar compounds might be promising therapeutic tools for heroin use disorder,” said Dr. Hurd.
The analogous epigenetic impairments found in the heroin-taking rats also indicate this animal model will be useful in further studies to identify addiction-related changes that translate to the human brain.
Notes for editors
The article is "Striatal H3K27 Acetylation Linked to Glutamatergic Gene Dysregulation in Human Heroin Abusers Holds Promise as Therapeutic Target," by Gabor Egervari, Joseph Landry, James Callens, John F. Fullard, Panos Roussos, Eva Keller, and Yasmin L. Hurd (http://dx.doi.org/10.1016/j.biopsych.2016.09.015). It appears in Biological Psychiatry, volume 81, issue 7 (2017), published by Elsevier.
Copies of this paper are available to credentialed journalists upon request; please contact Rhiannon Bugno at +1 214 648 0880 or email@example.com. Journalists wishing to interview the authors may contact Yasmin Hurd, Ph.D., at Yasmin.Hurd@mssm.edu.
The authors’ affiliations, and disclosures of financial and conflicts of interests are available in the article.
John H. Krystal, M.D., is Chairman of the Department of Psychiatry at the Yale University School of Medicine, Chief of Psychiatry at Yale-New Haven Hospital, and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here.
About Biological Psychiatry
Biological Psychiatry is the official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.
The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.
Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 5th out of 140 Psychiatry titles and 11th out of 256 Neurosciences titles in the Journal Citations Reports® published by Thomson Reuters. The 2015 Impact Factor score for Biological Psychiatry is 11.212.
Elsevier is a global information analytics company that helps institutions and professionals progress science, advance healthcare and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, more than 35,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com
Editorial Office, Biological Psychiatry
+1 214 648 0880